Compass is still being developed and is effectively in beta. Some content and features may be incomplete, change, or not work as expected.

Content is anchored to trusted sources where available, but Compass has not yet been clinically reviewed. It provides general information rather than medical advice.

Feedback helps us identify gaps, errors, usability problems and opportunities to improve Compass over time.

NUZ-001 arm in HEALEY ALS trial expands to 240 participants

Original source

NUZ-001 arm in HEALEY ALS trial expands to 240 participantsBioNews, Inc. · 3 June 2026

Compass holds only the headline and link for this source, so the summary below is necessarily brief. Please read the original.

The NUZ-001 arm of the HEALEY ALS trial is expanding to 240 participants, according to ALS News Today. The report does not provide results or treatment information.

Why this matters

The expansion means more people may be enrolled in this trial arm. It does not show that NUZ-001 is effective or changes treatment for people living with ALS.

Limitations and context

This is based only on the title and metadata of a news report. The available source provides no study design, participant details, results, or peer-review information, so the expansion and its implications cannot be assessed further.

Relevant to you?